Cipla to sell 51 percent stake in Uganda arm for USD 25-30 million
Advertisement
Mumbai: Pharma major Cipla Limited and its wholly owned subsidiaries, Cipla (EU) Limited, UK and Meditab Holdings Limited, Mauritius, have entered into a Share Purchase Agreement with Africa Capitalworks SSA 3 for the sale of 51.18 percent stake in Cipla Quality Chemical Industries Limited (CQCIL), Uganda. Subsequent to the sale, CQCIL will cease to be a subsidiary of Cipla.
"Consideration to be received by Cipla (EU) Limited and Meditab Holdings Limited shall be in the range of USD 25-30 million which shall be subject to annualised audited EBITDA of CQCIL for FY23 and other adjustments as agreed between the parties and stated in the Share Purchase Agreement," the company stated in a recent BSE filing.
The proposed sale is expected to be completed by 31st May 2023, subject to obtaining regulatory approvals and completion of conditions precedent as mutually agreed between the parties.
The buyer, Africa Capitalworks SSA 3, is a wholly owned subsidiary of Africa Capitalworks Holdings (“ACW”), an investment management company incorporated in Mauritius. ACW is engaged in providing permanent equity capital and complementary skills to mid‐market companies across Sub‐Saharan Africa.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.